Benefits

Prostate Px is useful to physicians because it provides objective analysis of the patient’s biopsy tissue enabling more-informed, actionable decisions prior to prostate cancer treatment selection.

Primary Benefits

• A subset of patients who present clinically as low-risk (biopsy Gleason <6, PSA <10 ng/ml, clinical stage T1, T2a) can have aggressive disease: Prostate Px can unmask these high-risk cases
• Patients classified by American Urological Association (AUA) guidelines as medium or intermediate-risk can now be assessed as high or low-risk prior to prostate cancer treatment selection
• Prostate Px can help assess indolent disease defined by favorable pathology
• Prostate Px provides an objective recurrence score that can be used to support patient counseling

Additional Benefits

Prostate Px provides an endpoint based on a cohort of prostatectomy patients. But, because prostatectomy is considered the gold standard for treatment, Prostate Px information can still be useful in other scenarios.

• Unlike prostatectomy, patients considering radiotherapy (EBRT or brachytherapy) will only have one biopsy-based tissue view of the disease: radiotherapy treatments destroy the tissue. Prostate Px provides a unique perspective on these patients' disease severity, prior to therapy, that is unavailable by any other method
• Patients considering brachytherapy, active surveillance or cryotherapy, as well as surgery can make more informed decisions based upon Prostate Px results